New -Lactamase Inhibitors Nacubactam and Zidebactam Improve the in Vitro Activity of -Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

Research output: Contribution to journalArticle

Abstract

The new diazabicyclooctane-based -lactamase inhibitors avibactam and relebactam improve the in vitro activity of -lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based -lactamase inhibitors in clinical development, nacubactam and zidebactam, with -lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner -lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other -lactams, similar to prior results with avibactam and relebactam.

Original languageEnglish (US)
Article numbere00733-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lactams
Mycobacterium
Anti-Bacterial Agents
meropenem
Bacteria
In Vitro Techniques
MK-7655
avibactam

Keywords

  • -lactamase inhibitors
  • -lactams
  • Cefepime
  • Diazabicyclooctane
  • Drug susceptibility assay
  • Meropenem
  • Mycobacterium abscessus
  • Nacubactam
  • Zidebactam

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{13f1dbbd373f4e79a6d7198cce7c8092,
title = "New -Lactamase Inhibitors Nacubactam and Zidebactam Improve the in Vitro Activity of -Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates",
abstract = "The new diazabicyclooctane-based -lactamase inhibitors avibactam and relebactam improve the in vitro activity of -lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based -lactamase inhibitors in clinical development, nacubactam and zidebactam, with -lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner -lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other -lactams, similar to prior results with avibactam and relebactam.",
keywords = "-lactamase inhibitors, -lactams, Cefepime, Diazabicyclooctane, Drug susceptibility assay, Meropenem, Mycobacterium abscessus, Nacubactam, Zidebactam",
author = "Amit Kaushik and Nicole Ammerman and Parrish, {Nicole M} and Eric Nuermberger",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/AAC.00733-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - New -Lactamase Inhibitors Nacubactam and Zidebactam Improve the in Vitro Activity of -Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

AU - Kaushik, Amit

AU - Ammerman, Nicole

AU - Parrish, Nicole M

AU - Nuermberger, Eric

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The new diazabicyclooctane-based -lactamase inhibitors avibactam and relebactam improve the in vitro activity of -lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based -lactamase inhibitors in clinical development, nacubactam and zidebactam, with -lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner -lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other -lactams, similar to prior results with avibactam and relebactam.

AB - The new diazabicyclooctane-based -lactamase inhibitors avibactam and relebactam improve the in vitro activity of -lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based -lactamase inhibitors in clinical development, nacubactam and zidebactam, with -lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner -lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other -lactams, similar to prior results with avibactam and relebactam.

KW - -lactamase inhibitors

KW - -lactams

KW - Cefepime

KW - Diazabicyclooctane

KW - Drug susceptibility assay

KW - Meropenem

KW - Mycobacterium abscessus

KW - Nacubactam

KW - Zidebactam

UR - http://www.scopus.com/inward/record.url?scp=85071254791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071254791&partnerID=8YFLogxK

U2 - 10.1128/AAC.00733-19

DO - 10.1128/AAC.00733-19

M3 - Article

C2 - 31209013

AN - SCOPUS:85071254791

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

M1 - e00733-19

ER -